Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato

Even though it's been a terrible year for healthcare stocks, there are still a handful of real winners like Johnson and Johnson up more than 24% year to date. I think that's because of their incredible research work and their remarkable pipeline. It's differentiating itself from the pack.So, can this pharma and medtech titan keep climbing. Let's take a closer look with walking data. He's the chairman and CEO of Johnson.Mr. . D, welcome back to Buddy. Thank you, Jean, for having me here.I love your five reas ...